TKI discontinuation on CML patients—molecular BCR::ABL1 quantification is an essential requirement for the treatment-free remission protocol, as patients must be on TKI with DMR for two years to be eligible. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.